Literature DB >> 26573420

Can FCR be curative in CLL?

David Killock.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26573420     DOI： 10.1038/nrclinonc.2015.206

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  2 in total

1.  Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.

Authors:  Kirsten Fischer; Jasmin Bahlo; Anna Maria Fink; Valentin Goede; Carmen Diana Herling; Paula Cramer; Petra Langerbeins; Julia von Tresckow; Anja Engelke; Christian Maurer; Gabor Kovacs; Marco Herling; Eugen Tausch; Karl-Anton Kreuzer; Barbara Eichhorst; Sebastian Böttcher; John F Seymour; Paolo Ghia; Paula Marlton; Michael Kneba; Clemens-Martin Wendtner; Hartmut Döhner; Stephan Stilgenbauer; Michael Hallek
Journal:  Blood       Date:  2015-10-20       Impact factor: 22.113

2.  Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.

Authors:  Philip A Thompson; Constantine S Tam; Susan M O'Brien; William G Wierda; Francesco Stingo; William Plunkett; Susan C Smith; Hagop M Kantarjian; Emil J Freireich; Michael J Keating
Journal:  Blood       Date:  2015-10-22       Impact factor: 22.113
  2 in total
  1 in total

1.  Subtype assignment of CLL based on B-cell subset associated gene signatures from normal bone marrow - A proof of concept study.

Authors:  Caroline Holm Nørgaard; Lasse Hjort Jakobsen; Andrew J Gentles; Karen Dybkær; Tarec Christoffer El-Galaly; Julie Støve Bødker; Alexander Schmitz; Preben Johansen; Tobias Herold; Karsten Spiekermann; Jennifer R Brown; Josephine L Klitgaard; Hans Erik Johnsen; Martin Bøgsted
Journal:  PLoS One       Date:  2018-03-07       Impact factor: 3.752
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.